在体外的药物基因学方法揭示了非典型的形/形瘤 (AT/RT) 中的亚型特异性治疗脆弱性

相关实验视频

Updated: May 27, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.5K

David Pauck1, Daniel Picard2, Mara Maue3

  • 1Institute of Neuropathology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany; Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich Heine University Düsseldorf, Medical Faculty, and University Hospital Düsseldorf, Düsseldorf, Germany; German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Düsseldorf, Germany.

Pharmacological research
|February 17, 2025
PubMed
概括

非典型的形形/形形瘤 (AT/RT) 显示出特定亚型的药物脆弱性. 这项研究确定了对AT/RT有效的MEK和MDM2抑制剂,在AT/RT-SHH和AT/RT-MYC亚型中观察到不同的反应.

关键词:
17-AAG/tanespimycin (PubChem CID:6505803) 是一个可以被认为是17-AAG/tanespimycin的药物.ABT-199/venetoclax (PubChem CID: 49846579) 是一家在美国的公司.ABT-737 (PubChem CID: 11228183) 这是一个非常重要的数字.非典型的甲状腺/状腺瘤.基因组甲基化概况的DNA甲基化分析GDC-0623 (PubChem CID: 42642654) 这是一项研究.高通量药物查的高通量药物查有关RNA测序的RNA测序有针对性的治疗.布里西克利布 (PubChem CID: 11248490) 的使用情况伊达萨努特林 (PubChem CID: 53358942) 是一个有趣的药物.乌姆布林化 (PubChem CID: 6918404) 的使用情况

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.1K

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K